ENTERA BIO LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.31 USD | -2.94% |
|
-11.15% | +285.00% |
Presentation Operator MessageOperator (Operator)Hello, everyone, and welcome to Entera Bio's I...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Calendar
01/06/2024
- Endocrine Society Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.31
USD
Average target price
10
USD
Spread / Average Target
+332.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +285.00% | 82.66M | |
| +10.79% | 116B | |
| +11.65% | 106B | |
| -6.20% | 23.89B | |
| -2.33% | 21.58B | |
| -6.03% | 18.96B | |
| -13.41% | 16.33B | |
| -40.50% | 16.96B | |
| +6.64% | 14.14B | |
| +31.84% | 12.02B |
- Stock Market
- Equities
- ENTX Stock
- News Entera Bio Ltd.
- Transcript : Entera Bio Ltd. - Special Call
